γδ T cells BiTE back at small cell lung cancer.

γδ T cells activated by a BiTE can target small cell lung cancer independently of MHC-I expression, overcoming limitations of CD8+ T cell responses.

• Why it matters: Effective immunotherapy for small cell lung cancer remains challenging due to low MHC-I expression and ineffective CD8+ T cell activity, necessitating alternative strategies.
• What they did: Ng et al. characterized cytotoxic γδ T cells in small cell lung cancer and used a bispecific T cell engager (BiTE) to activate Vδ2+ cells, bypassing MHC-I dependence.
• The result: This approach suggests that engaging γδ T cells with BiTEs may provide a promising immunotherapeutic avenue for small cell lung cancer resistant to checkpoint blockade.